In September 2022, Shanghai TopAlliance Biomedical Technology Co., Ltd. (referred as “TopAlliance”) and Shanghai BiBo Biomedical Engineering Co., Ltd. (referred as “BiBo Pharma”) signed a strategic cooperation agreement in Shanghai. According to the agreement, the two parties will carry out in-depth cooperation in biotech drug technology development and commercial production based on their respective core competencies. BiBo Pharma will provide TopAlliance with comprehensive CMC services based on its own mammalian cell culture, microbial fermentation, and AAV-based gene therapy technology platform, especially the largest single tank in the world built by BiBo Pharma in Lingang, Shanghai. The 30,000-liter stainless steel bioreactor provides TopAlliance with product commercial production solutions.
This cooperation coincides with TopAlliance’s efforts to further develop the macromolecular biological drug pipeline and seek stable operation. Besides, it will continue to help TopAlliance’s pipeline enter the commercialization stage and actively seek internationalization. `At the same time, this strategic cooperation between the two parties will also help the implementation of the “14th Five-Year Plan” for the biopharmaceutical industry in Shanghai. In the face of the current business challenges, the company has provided a new breakthrough and development idea.
About TopAlliance
TopAlliance(688180.SH, 1877.HK), established in December 2012, is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. The company has a rich R&D pipeline consisting of more than 50 product candidates, covering five therapeutic areas, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurological diseases and infectious diseases.
